High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
Am J Respir Crit Care Med
.
2020 Jun 15;201(12):1578-1579.
doi: 10.1164/rccm.202001-0201LE.
Authors
Tom Decroo
1
2
,
Bouke C de Jong
1
,
Alberto Piubello
3
4
,
Mahamadou Bassirou Souleymane
3
,
Lutgarde Lynen
1
,
Armand Van Deun
5
Affiliations
1
Institute of Tropical MedicineAntwerp, Belgium.
2
Research Foundation FlandersBrussels, Belgium.
3
Damien FoundationNiamey, Niger.
4
International Union Against Tuberculosis and Lung DiseaseParis, Franceand.
5
Independent ConsultantLeuven, Belgium.
PMID:
32130864
PMCID:
PMC7301730
DOI:
10.1164/rccm.202001-0201LE
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Isoniazid
Pyrazinamide
Rifampin
Tuberculosis*
Tuberculosis, Multidrug-Resistant*
Substances
Pyrazinamide
Isoniazid
Rifampin